Relmada Therapeutics, Inc. (RLMD) Financials
RLMD Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 109.1 million | 8.4 million |
2023-06-30 | 122.0 million | 10.7 million |
2023-03-31 | 135.6 million | 10.1 million |
2022-12-31 | 152.9 million | 12.5 million |
RLMD Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -11.6 million | 11.4 million |
2023-06-30 | -13.3 million | 11.2 million |
2023-03-31 | -16.5 million | 11.4 million |
2022-12-31 | -35.9 million | 11.6 million |
RLMD Net Income
No data available :(
RLMD Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 106.3 million | - | - |
2023-06-30 | 118.5 million | - | - |
2023-03-31 | 132.4 million | - | - |
2022-12-31 | 148.3 million | - | - |
RLMD Shares Outstanding
RLMD Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | - | 10.5 million | 12.2 million | - |
2023-06-30 | - | 13.7 million | 12.3 million | - |
2023-03-31 | - | 15.9 million | 12.3 million | - |
2022-12-31 | - | 26.9 million | 11.8 million | - |
RLMD Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | - | - |
2023-06-30 | - | - |
2023-03-31 | - | - |
2022-12-31 | - | - |
RLMD
Price: $3.68
52 week price:
Earnings Per Share: -3.28 USD
P/E Ratio: -1.51
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 144200
Market Capitalization: 146.6 million